Intravenous administration of human adipose-derived stem cells ameliorates motor and cognitive function for intracerebral hemorrhage mouse model

• Published in: Brain research Vol. 1711; pp. 58 - 67
• Main Authors: Kuramoto, Yoji, Takagi, Toshinori, Tatebayashi, Kotaro, Beppu, Mikiya, Doe, Nobutaka, Fujita, Mitsugu, Yoshimura, Shinichi
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 15.05.2019
• Subjects: Human adipose-derived stem cell; Intracerebral hemorrhage; Macrophage; Neurobehavior; Neurobehavior; Human adipose-derived stem cell; Intracerebral hemorrhage; Macrophage
• ISSN: 0006-8993; 1872-6240; 1872-6240
• DOI: 10.1016/j.brainres.2018.12.042

•Human adipose-derived stem cells improve ICH-induced neurological deficits.•The therapeutic effects are mediated by CD11b+CD45+ subpopulations.•Human adipose-derived stem cells can be served as a novel strategy for ICH treatment. Even today, intracerebral hemorrhage (ICH) is a major cause of death and disabilities. Rehabilitation is preferentially applied for functional recovery although its effect is limited. Recent studies have suggested that intravenous administration of mesenchymal stem cells would improve the post-ICH neurological deficits. Human adipose-derived stem cells (hADSCs) have been established in our laboratory. We aimed to evaluate the therapeutic efficacy of the hADSCs on the post-ICH neurological deficits using a clinical-relevant ICH mouse model. We also evaluated immune responses to clarify the underlying mechanisms. The hADSCs expressed MSC markers at high levels. The hADSCs administration into the ICH-bearing mice improved the neurological deficits during the subacute phases, which was shown by neurobehavioral experiments. Besides, the hADSC administration decreased the number of CD11+CD45+ cells and increased the proportion of CD86+ and Ly6C+ cells in the ICH lesions. In summary, intravenous administration of hADSCs during the acute phase improved ICH-induced neurological deficits during the subacute phase because of the suppression of acute inflammation mediated by CD11+CD45+ subpopulations. Our data suggest that hADSCs can be served as a novel strategy for ICH treatment.